Subcutaneous injection

Subcutaneous injection places a compound in the layer of fat between the skin and the muscle beneath it. Written subQ, SC or SQ. It is the default route for injectable peptides, insulin, and most self-administered biologics, and the reason is the tissue itself.

Subcutaneous fat has a relatively sparse blood supply compared with muscle. A depot deposited there is absorbed gradually rather than swept away, which produces a lower peak and a longer, flatter curve than the same dose given intramuscularly. For a compound intended to act over hours or days that is desirable, and it is why the route is chosen rather than tolerated.

How this changes the pharmacokinetics

When absorption from the depot is slower than the body's ability to clear the compound, absorption becomes the rate-limiting step. The measured half-life then describes how fast the depot empties rather than how fast the body eliminates.

This has a consequence worth holding onto: a half-life quoted without a route is close to meaningless for an injectable peptide. The same molecule can show a substantially longer apparent half-life subcutaneously than intravenously, and the difference is the tissue, not the chemistry.

Site changes the number

Absorption is not uniform across the body. The abdomen is generally the fastest of the commonly used sites, with the thigh and buttock slower, and the arm intermediate. The differences are well characterised for insulin and follow from local blood flow.

Several things shift that further. Exercising a limb increases blood flow to it and speeds absorption from a site on it. Heat, from a hot shower or a sauna, does the same. Cold slows it. And lipohypertrophy, the thickened tissue that builds where injections repeat in one spot, slows and destabilises absorption considerably.

Practically: switching sites between regions changes the absorption profile as well as avoiding tissue damage. That is a reason to be consistent about region and systematic about rotation within it, rather than to move at random.

What determines depth

The aim is the fat layer, not the muscle beneath. Whether a given needle reaches it depends on needle length and on the thickness of the tissue at that site, which varies by body composition and by region.

The guidance that comes out of the insulin literature is that short needles are generally sufficient for most adults, and that with a short needle a perpendicular injection is typically appropriate, while a longer needle may need a lifted skin fold or an angled entry to avoid reaching muscle. This is exactly the sort of thing to settle with whoever prescribed the medication rather than from a forum, because it depends on the person and the needle in question.

Injecting into muscle unintentionally does not usually cause harm, but it does change the absorption curve, which reintroduces the variability the route was chosen to avoid.

Volume, and why insulin syringes

The subcutaneous space accommodates only small volumes comfortably, generally well under a millilitre for a single site. Larger volumes cause pressure, discomfort and leakage back through the track.

That volume constraint is why insulin syringes are the standard tool. A U-100 syringe is graduated in units where 100 units equals 1 ml, so one unit is 0.01 ml, which gives readable graduations at the volumes involved. The reconstitution calculator converts a dose in micrograms into units on that scale.

Subcutaneous against the alternatives

Intramuscular places the dose into muscle, which is far better perfused. Absorption is faster and the peak is higher and earlier. That is desirable when speed matters, and it is the reason vaccines and some emergency medications go that route. For a compound meant to hold a level, it is the wrong shape of curve.

Intravenous skips absorption entirely. The whole dose is in circulation immediately, giving complete bioavailability and the highest, earliest peak. It also requires venous access and offers no way to slow things down once given.

Oral is not available to most peptides at all, which is the structural constraint behind this whole category. A peptide swallowed is a protein entering a digestive tract built to break proteins into amino acids. The few oral peptide products that exist required substantial formulation work to get any meaningful fraction past that, and their bioavailability remains low. It is the reason injection is the default rather than a preference.

Related terms: intramuscular, lipohypertrophy, insulin syringe, half-life.